Vivan renews five-year lease at UK biotech hub White City Place
The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma
Read More
Tag: Biotech
Gilead strikes $4.9bn deal to buy Forty Seven
The acquisition is set to strengthen Gilead’s immuno-oncology research and development portfolio with drugs such as Forty Seven’s magrolimab.
Read More
Thermo Fisher buys Brammer Bio for $1.7bn
Thermo Fisher is set to acquire Brammer Bio for approximately $1.7 billion.
Read More
Biotech growth in UK booms 65% since 2016
The number of active UK biotechnology businesses in the R&D field has soared by 65% in just over three years.
Read More
Current biopharma R&D costs ‘unsustainable’, warns report
Improving return on investment in R&D is “imperative” to the future success of global pharma and biotech companies, warns a new report by Ernst & Young.
Read More
UK biotech takes pole position in Europe
The UK has the strongest and most robust clinical pipeline in Europe, with the number of drug products in development higher in the UK than anywhere else in the region, according to a new report by the BioIndustry Association.
Read More
Astellas completes 800 million euro biotech acquisition
Belgium’s Ogeda is now a wholly-owned subsidiary of the Japanese pharma firm
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
